Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study

Cerebrovascular Diseases

Volumn 42, Issue 1-2, 2016, Pages 41-48

  Momosaki, Ryo ^a   Yasunaga, Hideo ^b   Kakuda, Wataru ^a   Matsui, Hiroki ^b   Fushimi, Kiyohide ^c   Abo, Masahiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Acute ischemic stroke; Cerebral hemorrhage; Early rehabilitation; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; INCIDENCE; JAPAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROREHABILITATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; THERAPY DELAY; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; CONVALESCENCE; DISABILITY; FACTUAL DATABASE; FIBRINOLYTIC THERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; STROKE; STROKE REHABILITATION; TIME FACTOR; TIME TO TREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RECOMBINANT PROTEINS; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; STROKE REHABILITATION; THROMBOLYTIC THERAPY; TIME FACTORS; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84961223756     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000444720     Document Type: Article

References (30)

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
2. Clark WM, Albers GW, Madden KP, Hamilton S: The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke 2000; 31: 811-816.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
4. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; Japan Alteplase Clinical Trial (J-ACT) Group: Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke 2006; 37: 1810-1815.
5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet 1998; 352: 1245-1251.
7. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET Investigators: Effects of alteplase beyond 3 h after stroke in the Echoplanar imaging thrombolytic evaluation trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
8. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, Peterson ED, Hernandez AF, Fonarow GC, Schwamm LH, Smith EE: Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 2012; 43: 2293-2299.
9. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, Wahlgren N, Ahmed N; SITS Investigators: Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe implementation of treatments in stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012; 43: 1524-1531.
10. Nadeau JO, Shi S, Fang J, Kapral MK, Richards JA, Silver FL, Hill MD; Investigators for the Registry of the Canadian Stroke Network: TPA use for stroke in the registry of the Canadian stroke network. Can J Neurol Sci 2005; 32: 433-439.
11. Alberts MJ, Latchaw RE, Jagoda A, Wechsler LR, Crocco T, George MG, Connolly ES, Mancini B, Prudhomme S, Gress D, Jensen ME, Bass R, Ruff R, Foell K, Armonda RA, Emr M, Warren M, Baranski J, Walker MD; Brain Attack Coalition: Revised and updated recommendations for the establishment of primary stroke centers: A summary statement from the brain attack coalition. Stroke 2011; 42: 2651-2665.
12. Murphy TH, Corbett D: Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 2009; 10: 861-872.
13. Bernhardt J, Dewey H, Thrift A, Collier J, Donnan G: A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke 2008; 39: 390-396.
14. Langhorne P, Stott D, Knight A, Bernhardt J, Barer D, Watkins C: Very early rehabilitation or intensive telemetry after stroke: A pilot randomised trial. Cerebrovasc Dis 2010; 29: 352-360.
15. Ha J, Churilov L, Linden T, Bernhardt J: Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services. Int J Stroke 2013; 8: 172-179.
16. Arnold SM, Dinkins M, Mooney LH, Freeman WD, Rawal B, Heckman MG, Davis OA: Very early mobilization in stroke patients treated with intravenous recombinant tissue plasminogen activator. J Stroke Cerebrovasc Dis 2015; 24: 1168-1173.
17. AVERT Trial Collaboration Group, Bernhardt J, Langhorne P, Lindley RI, Thrift AG, Ellery F, Collier J, Churilov L, Moodie M, Dewey H, Donnan G: Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): A randomised controlled trial. Lancet 2015; 386: 46-55.
18. Matsuda S, Ishikawa KB, Kuwabara K, Fujimori K, Fushimi K, Hashimoto H: Development and use of the Japanese case-mix system. Eurohealth 2008; 14: 27-30.
19. Sulter G, Steen C, De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999; 30: 1538-1541.
20. Saposnik G, Webster F, O'Callaghan C, Hachinski V: Optimizing discharge planning: clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke. Stroke 2005; 36: 147-150.
21. Ono K, Wada K, Takahara T, Shirotani T: Indications for computed tomography in patients with mild head injury. Neurol Med Chir 2007; 47: 291-297.
22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
23. Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003; 157: 364-375.
24. Brookhart MA, Rassen JA, Schneeweiss S: Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiol Drug Saf 2010; 19: 537-554.
25. Matsui H, Hashimoto H, Horiguchi H, Yasunaga H, Matsuda S: An exploration of the association between very early rehabilitation and outcome for the patients with acute ischaemic stroke in Japan: A nationwide retrospective cohort survey. BMC Health Serv Res 2010; 10: 213.
26. Staiger D, Stock JH: Instrumental variables regression with weak instruments. Econometrica 1994; 65: 557-586.
27. Carmichael ST: Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol 2006; 59: 735-742.
28. Biernaskie J, Chernenko G, Corbett D: Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. J Neurosci 2004; 24: 1245-1254.
29. Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF: Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair 2012; 26: 923-931.
30. Egan KJ, Janssen H, Sena ES, Longley L, Speare S, Howells DW, Spratt NJ, Macleod MR, Mead GE, Bernhardt J: Exercise reduces infarct volume and facilitates neurobehavioral recovery: results from a systematic review and meta-analysis of exercise in experimental models of focal ischemia. Neurorehabil Neural Repair 2014; 28: 800-812.